AVEO Oncology to Announce First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 5, 2022
AVEO Oncology (Nasdaq: AVEO) announced it will report its Q1 2022 financial results on May 5, 2022. The management team will hold a conference call at 8:30 a.m. ET on the same day to discuss the results and provide a business update. FOTIVDA® (tivozanib), the company's marketed product, targets advanced renal cell carcinoma in patients who have received prior systemic therapies. AVEO is also exploring further developments in immuno-oncology and other targeted treatments. The press release contains forward-looking statements with inherent risks and uncertainties.
- AVEO markets FOTIVDA® for advanced renal cell carcinoma, showing strong commercial focus.
- Ongoing development of FOTIVDA in immuno-oncology and other novel therapies indicates a commitment to expanding its product pipeline.
- None.
BOSTON, April 28, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that it will report first quarter 2022 financial results on Thursday, May 5, 2022. AVEO’s management team will host a conference call and audio webcast at 8:30 a.m. ET on Thursday, May 5, 2022, to discuss the financial results and provide a business update.
The call can be accessed by dialing (800) 954-1051 (U.S. and Canada) or (303) 223-0117 (international). The passcode for the conference call is 22018215. To access the live webcast, or the subsequent archived recording, please visit the Calendar of Events sub-section within the Investors section of the AVEO website at www.aveooncology.com.
About AVEO Pharmaceuticals, Inc.
AVEO is a commercial-stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer. AVEO currently markets FOTIVDA® (tivozanib) in the U.S. for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies. AVEO continues to develop FOTIVDA in immuno-oncology and other novel targeted combinations in RCC and other indications, and has other investigational programs in clinical development. AVEO is committed to creating an environment of diversity, equity and inclusion to diversify representation within the company.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements of AVEO within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Actual results or events could differ materially due to a number of important factors, including risks discussed in the sections titled “Risk Factor Summary,” “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Liquidity and Capital Resources” included in AVEO’s most recent Annual Report on Form 10-K, its quarterly reports on Form 10-Q and in other filings that AVEO makes with the SEC. The forward-looking statements in this press release represent AVEO’s views as of the date of this press release. AVEO anticipates that subsequent events and developments may cause its views to change. While AVEO may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. You should, therefore, not rely on these forward-looking statements as representing AVEO’s views as of any date other than the date of this press release.
AVEO:
Hans Vitzthum
LifeSci Advisors, LLC
Hans@LifeSciAdvisors.com
(617) 430-7578
Source: AVEO Oncology
FAQ
When will AVEO report its Q1 2022 financial results?
What time is the AVEO conference call scheduled for?
What product does AVEO currently market?
What is the primary focus of AVEO Oncology?
What risks are associated with AVEO's forward-looking statements?
